Cargando…
Combined Mucinous and Neuroendocrine Tumours of the Appendix Managed with Surgical Cytoreduction and Oxaliplatin-based Hyperthermic Intraperitoneal Chemotherapy
Appendiceal neoplasms account for 1% of appendectomy specimens. Common subtypes include mucinous cystadenoma, adenocarcinoma, and neuroendocrine tumors (NETs). The simultaneous presence of appendicular mucinous and NETs is a rare event. Depending on the tumors’ morphological distribution in the affe...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6424473/ https://www.ncbi.nlm.nih.gov/pubmed/30911451 http://dx.doi.org/10.7759/cureus.3894 |
_version_ | 1783404689965973504 |
---|---|
author | Hajjar, Roy Dubé, Pierre Mitchell, Andrew Sidéris, Lucas |
author_facet | Hajjar, Roy Dubé, Pierre Mitchell, Andrew Sidéris, Lucas |
author_sort | Hajjar, Roy |
collection | PubMed |
description | Appendiceal neoplasms account for 1% of appendectomy specimens. Common subtypes include mucinous cystadenoma, adenocarcinoma, and neuroendocrine tumors (NETs). The simultaneous presence of appendicular mucinous and NETs is a rare event. Depending on the tumors’ morphological distribution in the affected organ, they are qualified as either “collision” or “combined” tumours. We herein present the case of a 50-year-old male who presented with acute appendicitis and who was subsequently found to have pseudomyxoma peritonei (PMP) due to a perforated combined mucinous and neuroendocrine tumours. The patient was treated by right hemicolectomy and cytoreductive surgery (CRS) with oxaliplatin-based hyperthermic intraperitoneal chemotherapy (HIPEC). He was cancer free 20 months later. Due to the limited clinical experience with this presentation, no formal recommendations exist as to its management other than those applicable to each cancer alone. The efficacity of treatment on the long-term prognosis on these combined tumors is yet to be elucidated. |
format | Online Article Text |
id | pubmed-6424473 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-64244732019-03-25 Combined Mucinous and Neuroendocrine Tumours of the Appendix Managed with Surgical Cytoreduction and Oxaliplatin-based Hyperthermic Intraperitoneal Chemotherapy Hajjar, Roy Dubé, Pierre Mitchell, Andrew Sidéris, Lucas Cureus Pathology Appendiceal neoplasms account for 1% of appendectomy specimens. Common subtypes include mucinous cystadenoma, adenocarcinoma, and neuroendocrine tumors (NETs). The simultaneous presence of appendicular mucinous and NETs is a rare event. Depending on the tumors’ morphological distribution in the affected organ, they are qualified as either “collision” or “combined” tumours. We herein present the case of a 50-year-old male who presented with acute appendicitis and who was subsequently found to have pseudomyxoma peritonei (PMP) due to a perforated combined mucinous and neuroendocrine tumours. The patient was treated by right hemicolectomy and cytoreductive surgery (CRS) with oxaliplatin-based hyperthermic intraperitoneal chemotherapy (HIPEC). He was cancer free 20 months later. Due to the limited clinical experience with this presentation, no formal recommendations exist as to its management other than those applicable to each cancer alone. The efficacity of treatment on the long-term prognosis on these combined tumors is yet to be elucidated. Cureus 2019-01-16 /pmc/articles/PMC6424473/ /pubmed/30911451 http://dx.doi.org/10.7759/cureus.3894 Text en Copyright © 2019, Hajjar et al. http://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Pathology Hajjar, Roy Dubé, Pierre Mitchell, Andrew Sidéris, Lucas Combined Mucinous and Neuroendocrine Tumours of the Appendix Managed with Surgical Cytoreduction and Oxaliplatin-based Hyperthermic Intraperitoneal Chemotherapy |
title | Combined Mucinous and Neuroendocrine Tumours of the Appendix Managed with Surgical Cytoreduction and Oxaliplatin-based Hyperthermic Intraperitoneal Chemotherapy |
title_full | Combined Mucinous and Neuroendocrine Tumours of the Appendix Managed with Surgical Cytoreduction and Oxaliplatin-based Hyperthermic Intraperitoneal Chemotherapy |
title_fullStr | Combined Mucinous and Neuroendocrine Tumours of the Appendix Managed with Surgical Cytoreduction and Oxaliplatin-based Hyperthermic Intraperitoneal Chemotherapy |
title_full_unstemmed | Combined Mucinous and Neuroendocrine Tumours of the Appendix Managed with Surgical Cytoreduction and Oxaliplatin-based Hyperthermic Intraperitoneal Chemotherapy |
title_short | Combined Mucinous and Neuroendocrine Tumours of the Appendix Managed with Surgical Cytoreduction and Oxaliplatin-based Hyperthermic Intraperitoneal Chemotherapy |
title_sort | combined mucinous and neuroendocrine tumours of the appendix managed with surgical cytoreduction and oxaliplatin-based hyperthermic intraperitoneal chemotherapy |
topic | Pathology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6424473/ https://www.ncbi.nlm.nih.gov/pubmed/30911451 http://dx.doi.org/10.7759/cureus.3894 |
work_keys_str_mv | AT hajjarroy combinedmucinousandneuroendocrinetumoursoftheappendixmanagedwithsurgicalcytoreductionandoxaliplatinbasedhyperthermicintraperitonealchemotherapy AT dubepierre combinedmucinousandneuroendocrinetumoursoftheappendixmanagedwithsurgicalcytoreductionandoxaliplatinbasedhyperthermicintraperitonealchemotherapy AT mitchellandrew combinedmucinousandneuroendocrinetumoursoftheappendixmanagedwithsurgicalcytoreductionandoxaliplatinbasedhyperthermicintraperitonealchemotherapy AT siderislucas combinedmucinousandneuroendocrinetumoursoftheappendixmanagedwithsurgicalcytoreductionandoxaliplatinbasedhyperthermicintraperitonealchemotherapy |